MEDICAL SERVICES

CERTIFICATIONS

  • American Board of Psychiatry and Neurology, Psychiatry
  • American Board of Psychiatry and Neurology, Child and Adolescent Psychiatry

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Measurement-Based Care in the Treatment of Adolescents with Substance Use Disorders. Child Adolesc Psychiatr Clin N Am. 2020 10; 29(4):675-690. View abstract
  2. Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2020 09; 30(7):414-426. View abstract
  3. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. J Am Acad Child Adolesc Psychiatry. 2020 10; 59(10):1107-1124. View abstract
  4. Development of a Composite Primary Outcome Score for Children with Attention-Deficit/Hyperactivity Disorder and Emotional Dysregulation. J Child Adolesc Psychopharmacol. 2020 04; 30(3):166-172. View abstract
  5. Practice Parameter for the Assessment and Treatment of Psychiatric Disorders in Children and Adolescents With Intellectual Disability (Intellectual Developmental Disorder). J Am Acad Child Adolesc Psychiatry. 2020 04; 59(4):468-496. View abstract
  6. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Focus (Am Psychiatr Publ). 2019 Apr; 17(2):158-162. View abstract
  7. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018 01 01; 175(1):86-90. View abstract
  8. Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings. J Am Acad Child Adolesc Psychiatry. 2017 Dec; 56(12):1026-1033. View abstract
  9. Forward to the Future: Clinical Updates and Clinical Practice Guidelines. J Am Acad Child Adolesc Psychiatry. 2017 10; 56(10):811-812. View abstract
  10. Challenges and Gaps in Understanding Substance Use Problems in Transitional Age Youth. Child Adolesc Psychiatr Clin N Am. 2017 04; 26(2):253-269. View abstract
  11. Comparing treatments for children with ADHD and word reading difficulties: A randomized clinical trial. J Consult Clin Psychol. 2017 May; 85(5):434-446. View abstract
  12. The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders. J Child Adolesc Psychopharmacol. 2017 02; 27(1):52-65. View abstract
  13. Attributions and Perception of Methylphenidate Effects in Adolescents With ADHD. J Atten Disord. 2017 01; 21(2):129-136. View abstract
  14. Acute Effects of MPH on the Parent-Teen Interactions of Adolescents With ADHD. J Atten Disord. 2017 01; 21(2):158-167. View abstract
  15. The Effectiveness of Short- and Long-Acting Stimulant Medications for Adolescents With ADHD in a Naturalistic Secondary School Setting. J Atten Disord. 2017 01; 21(1):40-45. View abstract
  16. Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory. J Child Adolesc Psychopharmacol. 2017 03; 27(2):117-124. View abstract
  17. Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. J Am Acad Child Adolesc Psychiatry. 2016 06; 55(6):469-78. View abstract
  18. Substance Use Disorders Among Adolescents. Focus (Am Psychiatr Publ). 2016 Jan; 14(1):57-59. View abstract
  19. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):203-12. View abstract
  20. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):213-24. View abstract
  21. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):225-33. View abstract
  22. Factor Validity of a Proactive and Reactive Aggression Rating Scale. J Child Fam Stud. 2015 Sep 01; 24(9):2734-2744. View abstract
  23. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2014 Oct; 53(10):1092-101. View abstract
  24. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. J Am Acad Child Adolesc Psychiatry. 2014 Sep; 53(9):948-959.e1. View abstract
  25. Treatment development and feasibility study of family-focused treatment for adolescents with bipolar disorder and comorbid substance use disorders. J Psychiatr Pract. 2014 May; 20(3):237-48. View abstract
  26. Evaluation of a booster intervention three years after acute treatment for early-onset disruptive behavior disorders. J Abnorm Child Psychol. 2014; 42(3):383-98. View abstract
  27. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2014 Jan; 53(1):47-60.e1. View abstract
  28. Personality-targeted interventions delivered by teachers may be effective at reducing alcohol use. Evid Based Ment Health. 2013 Nov; 16(4):100. View abstract
  29. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol. 2013 Jun; 23(5):337-51. View abstract
  30. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder. Expert Opin Pharmacother. 2012 Oct; 13(15):2207-13. View abstract
  31. Taking note of over-the-counter remedies for adolescents with cannabis dependence. Am J Psychiatry. 2012 Aug; 169(8):771-3. View abstract
  32. Attention deficit hyperactivity disorder and substance use disorders. Curr Top Behav Neurosci. 2012; 9:145-72. View abstract
  33. Predicting Treatment Response for Oppositional Defiant and Conduct Disorder Using Pre-treatment Adrenal and Gonadal Hormones. J Child Fam Stud. 2012 Dec; 21(6):973-981. View abstract
  34. Practice parameter for child and adolescent forensic evaluations. J Am Acad Child Adolesc Psychiatry. 2011 Dec; 50(12):1299-312. View abstract
  35. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012 Jan; 51(1):74-85.e2. View abstract
  36. The treatment of severe child aggression (TOSCA) study: Design challenges. Child Adolesc Psychiatry Ment Health. 2011 Nov 10; 5(1):36. View abstract
  37. Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents. Addict Behav. 2011 Aug; 36(8):843-8. View abstract
  38. Medication refusal in children with oppositional defiant disorder or conduct disorder and comorbid attention-deficit/hyperactivity disorder: medication history and clinical correlates. J Child Adolesc Psychopharmacol. 2011 Feb; 21(1):57-66. View abstract
  39. Influence of treatment for disruptive behavior disorders on adrenal and gonadal hormones in youth. J Clin Child Adolesc Psychol. 2011; 40(4):562-71. View abstract
  40. Clinical practice guidelines for attention-deficit/hyperactivity disorder: a review. Postgrad Med. 2010 Sep; 122(5):69-77. View abstract
  41. Management of the adolescent with substance use disorders and comorbid psychopathology. Child Adolesc Psychiatr Clin N Am. 2010 Jul; 19(3):609-23. View abstract
  42. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend. 2010 Nov 01; 112(1-2):39-45. View abstract
  43. Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. J Am Acad Child Adolesc Psychiatry. 2010 Apr; 49(4):414-30. View abstract
  44. Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Curr Med Res Opin. 2010 Jan; 26(1):129-37. View abstract
  45. Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child Adolesc Psychiatry Ment Health. 2009 Dec 10; 3(1):39. View abstract
  46. Comorbid substance use disorders among youth with bipolar disorder: opportunities for early identification and prevention. J Clin Psychiatry. 2010 Mar; 71(3):348-58. View abstract
  47. Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009 Oct; 19(5):511-7. View abstract
  48. The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry. 2009 Oct; 48(10):987-996. View abstract
  49. Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry. 2009 Oct; 48(10):997-1004. View abstract
  50. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther. 2009 Aug; 31(8):1844-55. View abstract
  51. Community vs. clinic-based modular treatment of children with early-onset ODD or CD: a clinical trial with 3-year follow-up. J Abnorm Child Psychol. 2009 Jul; 37(5):591-609. View abstract
  52. Substance use disorders and ADHD. CNS Spectr. 2009 Jul; 14(7 Suppl 6):10-1; discussion 13-4. View abstract
  53. Transdermal methylphenidate system: old wine in a new bottle. Expert Opin Drug Metab Toxicol. 2009 Jun; 5(6):661-5. View abstract
  54. Brief screens for detecting alcohol use disorder among 18-20 year old young adults in emergency departments: Comparing AUDIT-C, CRAFFT, RAPS4-QF, FAST, RUFT-Cut, and DSM-IV 2-Item Scale. Addict Behav. 2009 Aug; 34(8):668-74. View abstract
  55. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav. 2009 Oct; 34(10):905-9. View abstract
  56. Practice parameter for the psychiatric assessment and management of physically ill children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009 Feb; 48(2):213-33. View abstract
  57. Salivary gonadal and adrenal hormone differences in boys and girls with and without disruptive behavior disorders: Contextual variants. Biol Psychol. 2009 Apr; 81(1):31-9. View abstract
  58. Evidence of developmental alterations in cortical and subcortical regions of children with attention-deficit/hyperactivity disorder: a multivoxel in vivo phosphorus 31 spectroscopy study. Arch Gen Psychiatry. 2008 Dec; 65(12):1419-28. View abstract
  59. Substance use disorders in adolescents with attention-deficit/hyperactivity disorder. Adolesc Med State Art Rev. 2008 Aug; 19(2):242-53, viii. View abstract
  60. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2009 Jan; 12(4):308-15. View abstract
  61. Attention deficit hyperactivity disorder and substance use disorders. Child Adolesc Psychiatr Clin N Am. 2008 Apr; 17(2):309-23, viii. View abstract
  62. Sexual orientation and adolescent substance use: a meta-analysis and methodological review. Addiction. 2008 Apr; 103(4):546-56. View abstract
  63. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res. 2008 Mar; 41(3):250-7. View abstract
  64. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008 Feb; 47(2):180-188. View abstract
  65. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008 Feb; 47(2):189-198. View abstract
  66. Substance abuse in patients with attention-deficit/hyperactivity disorder. Medscape J Med. 2008 Jan 31; 10(1):24. View abstract
  67. Feasibility and preliminary efficacy of an after-school program for middle schoolers with ADHD: a randomized trial in a large public middle school. J Atten Disord. 2008 Nov; 12(3):207-17. View abstract
  68. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008 Jan; 69(1):149-59. View abstract
  69. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007 Nov; 46(11):1503-26. View abstract
  70. Changes and challenges: managing ADHD in a fast-paced world. J Manag Care Pharm. 2007 Nov; 13(9 Suppl B):S2-S13; quiz S14-S16. View abstract
  71. AACAP 2005 Research Forum: speeding the adoption of evidence-based practice in pediatric psychiatry. J Am Acad Child Adolesc Psychiatry. 2007 Sep; 46(9):1098-1110. View abstract
  72. Is attention-deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case-control study. Addiction. 2007 Jul; 102(7):1122-30. View abstract
  73. Regionally specific alterations in membrane phospholipids in children with ADHD: An in vivo 31P spectroscopy study. Psychiatry Res. 2006 Dec 01; 148(2-3):217-21. View abstract
  74. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006 Jun; 16(3):351-6. View abstract
  75. Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders. Expert Rev Neurother. 2006 Apr; 6(4):541-9. View abstract
  76. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006 Jan; 160(1):82-90. View abstract
  77. Clinical predictors of treatment in a population of adolescents with alcohol use disorders. Addict Behav. 2005 Oct; 30(9):1663-73. View abstract
  78. Alcohol use disorder symptoms and risk-taking behavior as predictors of alcohol-related medical events among young adults treated in emergency departments. Addict Behav. 2005 Oct; 30(9):1674-89. View abstract
  79. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. Addict Behav. 2005 Oct; 30(9):1824-33. View abstract
  80. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. J Am Acad Child Adolesc Psychiatry. 2005 Jun; 44(6):609-21. View abstract
  81. Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: a 3-year follow-up study. Addict Behav. 2005 May; 30(4):807-14. View abstract
  82. Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2005 Mar; 44(3):249-57. View abstract
  83. Alcohol use disorder in adolescents. Minerva Pediatr. 2005 Feb; 57(1):7-20. View abstract
  84. Treatment of co-occurring alcohol, drug, and psychiatric disorders. Recent Dev Alcohol. 2005; 17:349-65. View abstract
  85. Practice parameter for the assessment and treatment of children and adolescents with enuresis. J Am Acad Child Adolesc Psychiatry. 2004 Dec; 43(12):1540-50. View abstract
  86. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry. 2004 Dec; 43(12):1521-39. View abstract
  87. Salient variables for treatment research of adolescent alcohol and other substance use disorders. Addiction. 2004 Nov; 99 Suppl 2:23-37. View abstract
  88. Major depression associated with earlier alcohol relapse in treated teens with AUD. Addict Behav. 2004 Jul; 29(5):1035-8. View abstract
  89. Satisfaction with treatment for attention-deficit/hyperactivity disorder. Am J Manag Care. 2004 Jul; 10(4 Suppl):S107-16. View abstract
  90. Interventions in suicidal alcoholics. Alcohol Clin Exp Res. 2004 May; 28(5 Suppl):89S-96S. View abstract
  91. Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation. J Child Adolesc Psychopharmacol. 2004; 14(1):33-8. View abstract
  92. Clinical practices in the pharmacological treatment of comorbid psychopathology in adolescents with alcohol use disorders. J Subst Abuse Treat. 2003 Dec; 25(4):293-5. View abstract
  93. Psychiatric disorders among older adolescents treated in emergency departments on weekends: a comparison with a matched community sample. J Stud Alcohol. 2003 Sep; 64(5):616-22. View abstract
  94. Once-daily atomoxetine may reduce attention deficit hyperactivity disorder symptoms in children and adolescents. Evid Based Ment Health. 2003 May; 6(2):42. View abstract
  95. Alcohol and psychiatric comorbidity. Recent Dev Alcohol. 2003; 16:361-74. View abstract
  96. Attention-deficit/hyperactivity disorder and conduct disorder symptomatology in adolescents with alcohol use disorder. Psychol Addict Behav. 2002 Jun; 16(2):161-4. View abstract
  97. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002 Feb; 41(2 Suppl):26S-49S. View abstract
  98. Practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions, with special reference to seclusion and restraint. J Am Acad Child Adolesc Psychiatry. 2002 Feb; 41(2 Suppl):4S-25S. View abstract
  99. Alcohol use disorders in adolescents: epidemiology, diagnosis, psychosocial interventions, and pharmacological treatment. Paediatr Drugs. 2002; 4(8):493-502. View abstract
  100. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2001 Nov; 40(11):1352-5. View abstract
  101. Summary of the practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions with special reference to seclusion and restraint. J Am Acad Child Adolesc Psychiatry. 2001 Nov; 40(11):1356-8. View abstract
  102. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001 Oct; 108(4):883-92. View abstract
  103. Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial. Addict Behav. 2001 Sep-Oct; 26(5):735-9. View abstract
  104. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol. 2001 May; 9(2):163-75. View abstract
  105. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001 Feb; 40(2):180-7. View abstract
  106. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001 Feb; 40(2):188-96. View abstract
  107. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. J Abnorm Child Psychol. 2000 Dec; 28(6):507-25. View abstract
  108. Inter-rater reliability of the SCID alcohol and substance use disorders section among adolescents. Drug Alcohol Depend. 2000 May 01; 59(2):173-6. View abstract
  109. Disruptive behavior disorders and substance use disorders in adolescents. J Psychoactive Drugs. 2000 Jan-Mar; 32(1):67-79. View abstract
  110. Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry. 1999 May; 38(5):578-86. View abstract
  111. Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder. J Clin Child Psychol. 1998 Oct; 27(3):340-51. View abstract
  112. Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. Exp Clin Psychopharmacol. 1998 May; 6(2):187-204. View abstract
  113. Psychopathology in adolescent alcohol abuse and dependence. Alcohol Health Res World. 1998; 22(2):117-21, 126. View abstract
  114. Practice parameters for the assessment and treatment of children and adolescents with substance use disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997 Oct; 36(10 Suppl):140S-56S. View abstract
  115. Gender and comorbid psychopathology in adolescents with alcohol dependence. J Am Acad Child Adolesc Psychiatry. 1997 Sep; 36(9):1195-203. View abstract
  116. Identifying anxiety disorders in adolescents hospitalized for alcohol abuse or dependence. Psychiatr Serv. 1995 Jun; 46(6):618-20. View abstract
  117. Self-reported health problems and physical symptomatology in adolescent alcohol abusers. J Adolesc Health. 1995 Mar; 16(3):226-31. View abstract
  118. Cognitive distortions and adolescent affective disorder. Validity of the CNCEQ in an inpatient sample. Children's Negative Cognitive Error Questionnaire. Behav Modif. 1994 Jul; 18(3):339-51. View abstract
  119. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1994 Jul-Aug; 33(6):792-4. View abstract
  120. Cognitive distortions and psychiatric diagnosis in dually diagnosed adolescents. J Am Acad Child Adolesc Psychiatry. 1994 Feb; 33(2):217-22. View abstract
  121. Treatment of Adolescent Alcohol Abuse and Dependence. Alcohol Health Res World. 1994; 18(4):296-301. View abstract
  122. Risk factors for completed suicide among adolescents with a lifetime history of substance abuse: a case-control study. Acta Psychiatr Scand. 1993 Dec; 88(6):403-8. View abstract
  123. Drug abuse prevention for high-risk African American children and their families: a review and model program. Addict Behav. 1993 Mar-Apr; 18(2):213-34. View abstract
  124. Social skills and depression in adolescent substance abusers. Addict Behav. 1993 Jan-Feb; 18(1):9-18. View abstract
  125. Patterns of polydrug use in adolescent alcohol abusers. Am J Drug Alcohol Abuse. 1993; 19(4):511-21. View abstract
  126. Comparison between treatment completers and noncompleters among dually diagnosed substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry. 1992 Nov; 31(6):1046-9. View abstract
  127. Patterns of affective comorbidity in a clinical population of dually diagnosed adolescent substance abusers. J Am Acad Child Adolesc Psychiatry. 1992 Nov; 31(6):1041-5. View abstract
  128. Maltreatment in psychiatrically hospitalized dually diagnosed adolescent substance abusers. J Am Acad Child Adolesc Psychiatry. 1992 Sep; 31(5):868-74. View abstract
  129. The Teen-Addiction Severity Index: rationale and reliability. Int J Addict. 1991 Feb; 26(2):219-26. View abstract
  130. Multivariate comparison of adolescent offspring of substance abuse parents: community and treatment samples. J Subst Abuse. 1991; 3(3):301-6. View abstract
  131. Drug abuse severity in adolescents is associated with magnitude of deviation in temperament traits. Br J Addict. 1990 Nov; 85(11):1501-4. View abstract
  132. Reliability and validity of the structured interview for personality disorders in adolescents. J Am Acad Child Adolesc Psychiatry. 1990 May; 29(3):349-54. View abstract
  133. Comorbidity of substance abuse and other psychiatric disorders in adolescents. Am J Psychiatry. 1989 Sep; 146(9):1131-41. View abstract
  134. Adolescent chemical use and dependence: current issues in epidemiology, treatment and prevention. Acta Psychiatr Scand. 1989 May; 79(5):415-24. View abstract
  135. Teen Addiction Severity Index (T-ASI): clinical and research implications: a preliminary report. NIDA Res Monogr. 1989; 95:363. View abstract